Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction by Olga Gruzdeva et al.
ORIGINAL RESEARCH
published: 26 September 2016
doi: 10.3389/fphar.2016.00324
Frontiers in Pharmacology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 324
Edited by:
Ying Yu,
Shanghai Institutes for Biological
Sciences, Chinese Academy of
Sciences, China
Reviewed by:
Yu Li,
Shanghai Institutes for Biological
Sciences, Chinese Academy of
Sciences, China
Zhe Zheng,
Chinese Academy of Medical
Sciences and Peking Union Medical
College, China
*Correspondence:
Evgenya Uchasova
evg.uchasova@yandex.ru
Specialty section:
This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 30 May 2016
Accepted: 05 September 2016
Published: 26 September 2016
Citation:
Gruzdeva O, Uchasova E, Dyleva Y,
Akbasheva O, Karetnikova V and
Barbarash O (2016) Early Effects of
Treatment Low-Dose Atorvastatin on
Markers of Insulin Resistance and
Inflammation in Patients with
Myocardial Infarction.
Front. Pharmacol. 7:324.
doi: 10.3389/fphar.2016.00324
Early Effects of Treatment Low-Dose
Atorvastatin on Markers of Insulin
Resistance and Inflammation in
Patients with Myocardial Infarction
Olga Gruzdeva 1, Evgenya Uchasova 1*, Yulia Dyleva 1, Olga Akbasheva 2,
Victoria Karetnikova 1 and Olga Barbarash 1
1 Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Disease, Kemerovo, Russia,
2 State Budget Educational Institution of Higher Professional Education “Siberian State Medical University” of the Russian
Federation Ministry of Health, Tomsk, Russia
Dyslipidemia is one of the primary causes of cardiovascular disease. Therefore, attention
has been focused on the development of drugs that normalize lipid levels and exert
an effect on markers of atherothrombosis, insulin resistance (IR), and inflammation.
Atorvastatin is a drug with not only lipid-lowering potential, but it has multiple non-lipid
effects. This study aimed to evaluate atorvastatin effects on lipid, adipokine, IR, and
inflammatory statuses in patients with myocardial infarction (MI) in an in-hospital setting.
This study included 66 patients with confirmed ST-segment elevation MI, who were
treated with atorvastatin 20mg/day starting on day 1 of MI, without any dose changes.
The comparison group consisted of 60 patients receiving standard anti-anginal and
anti-thrombotic therapy. During the hospital stay, both groups showed a reduction in
total cholesterol level and free fatty acids and increased concentrations of apolipoprotein
A, especially those patients receiving atorvastatin. On day 1 of MI, patients in both
groups had elevated levels of leptin by 2.9- to 3.3-fold, but the leptin levels decreased
by 40.3% and were significantly lower than in patients not taking statins. The treatment
with atorvastatin was associated with a decrease in C-reactive protein and interleukin-6
by 23.1 and 49.2%, respectively, compared with baseline values. In the group of patients
on standard therapy, there was a decrease of interleukin-6 by 31.7%. Atorvastatin
administered early on during hospitalization to patients with MI contributed to the
improvement of lipid, adipokine and pro-inflammatory statuses and decreased IR.
Keywords: statin, myocardial infarction, inflammation, adipokine, lipid
INTRODUCTION
Despite recent advances in treatment options aimed at reducing the rate of ischemic events in the
first days following disease onset, patients with myocardial infarction (MI) remain at high risk of
cardiovascular events. Approximately 38% of women and 25% ofmenwill die within 1 year of a first
recognized heart attack (Rosamond et al., 2008). These data suggest the need to develop clinically
effective strategies to target pathophysiological mechanisms responsible for the development and
course of MI.
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Dyslipidemia is one of the major causes of MI that is
considered a complex multifactorial disease. Recently, insulin
resistance (IR) has been included as a potential risk factor
for MI. Its development is associated with a diverse set of
interrelated pathological mechanisms, namely atherothrombosis.
These mechanisms involve the activation of local and progressive
inflammatory processes in the atherosclerotic plaque concurrent
with endothelial dysfunction, which subsequently contribute to
the development of MI (Cefalu, 2001). Therefore, it is relevant to
develop drugs that can simultaneously normalize the maximum
number of elements involved in the pathogenesis of MI.
Taking into account that one of the major causes of
cardiovascular diseases is high circulating and tissue cholesterol
levels, drugs that not only improve impaired lipid transport,
but also exert beneficial effects on markers of atherothrombosis,
IR, and inflammation are necessary. One such promising drug
is atorvastatin, which is known to reduce cholesterol levels
by inhibiting hydroxymethylglutaryl-coenzyme A reductase. Its
beneficial effects are associated not only with its lipid-lowering
potential, but also with pleiotropic effects (improvement of
endothelial function, reduction of aseptic inflammation, among
others) according to results of long-term studies (Ichihara
and Satoh, 2002; Aronov, 2004; Rodríguez-Calvo et al., 2009).
Therefore, the study of the short-term effects of atorvastatin on
metabolic and functional disorders during early stages of MI
treatment could be useful to determine the prognosis and post-
MI management in this group of patients. The aim of this study
was to study the effects of atorvastatin on lipid parameters, leptin,
adiponectin, IR markers, plasminogen activator inhibitor type 1
(PAI-1), and inflammatory parameters in patients with MI in an
in-hospital setting.
METHODS
Ethical Considerations
The study protocol was approved by the Local Ethics Committee
of the Federal State Budgetary Institution Research Institute for
Complex Issues of Cardiovascular Diseases and was developed
according to WMA Declaration of Helsinki on Ethical Principles
for Medical Research Involving Human Subjects, 2000 edition,
and the “GCP Principles in the Russian Federation” approved
by the Russian Ministry of Health (19.06.2003). All patients gave
written informed consent.
Study Design
This was an open-label, prospective, comparative, controlled, 12
day study performed in Kemerovo Cardiology Dispensary in
2010. The inclusion criteria were as follows: confirmed diagnosis
of MI based on clinical, electrocardiographic, echocardiographic
findings, and biochemical features of the disease (Thygesen et al.,
2007). The exclusion criteria were as follows: statin therapy prior
to MI; serious diseases affecting prognosis, such as renal failure,
anemia, oncological diseases, hepatic failure, inflammatory, and
infectious disease during exacerbation; autoimmune diseases;
prolonged treatment with corticosteroids; and diabetes.
We included 66 patients with confirmed ST-segment elevation
MI, who received atorvastatin (atomax, JSC “Makiz Pharma,”
Russia) 20 mg/day starting on the first day of MI onset. The
dosage of atorvastatin was not increased (Group 1). The study
presents the results of observations during the period of 12
days from initial administration. The efficacy of atorvastatin was
assessed on 65 patients owing to one treatment discontinuation.
Therefore, the efficacy of atorvastatin therapy was assessed in 65
patients.
Sixty patients receiving standard anti-anginal and anti-
thrombotic therapy were retrospectively selected using a case-
control method from the ST-segment Elevation Acute Coronary
Syndrome Registry (n = 423) in the Kemerovo Cardiology
Dispensary between 2012 and 2013. These patients were included
in the comparison group (Group 2). Patients in this group did not
take statins during the pre-hospital or hospitalization periods.
The control group included 40 subjects (30 were male and 10
were female) aged 58 (56.3; 60.2) years, without cardiovascular
and endocrine disease, who were comparable to MI patients in
age and sex.
During the in-hospital period (mean period of 12 days), all the
patients (Group 1) received β-blockers, ACE inhibitors, calcium
channel blockers, diuretics, nitrates, aspirin, heparin, clopidogrel
and statins. Patients group 2 received all recommended
medications except statins.
Assays
The serum of each patient was separated from venous blood
by centrifugation at 3000 × g for 20min and stored at −70◦C.
On days 1 and 12 after MI onset, serum glucose, total
cholesterol (TC), triacylglycerol (TAG), free fatty acid (FFA),
low-density lipoprotein cholesterol (LDL), very-low-density
lipoprotein cholesterol, apolipoprotein B (apo-B), apolipoprotein
A1 (apo-A1), and high-density lipoprotein cholesterol (HDL)
levels were measured at the same study time-points using
standard Thermo Fisher Scientific test systems (Thermo Fisher
Scientific Oy, Vantaa, Finland) in a Konelab 30i biochemistry
analyzer (Thermo Fisher Scientific Oy). C-peptide measured by
ELISA with BioMedica (Sydney, Australia) and insulin levels
Diagnostic Systems Laboratories (Webster, TX, USA) laboratory
kits, respectively. The intra-assay coefficients of variation (CV)
for insulin and C-peptide ELISA were 3.8 and 4.2%, respectively,
and the inter-assay CVs were 6.9 and 7.9%, respectively.
Adipokine (leptin, adiponectin) levels were measured using
BioVendor assay kits (Brno, Czech Republic) and intra-assay
CVs were 5.9 and 6.8%. Patient prothrombotic potential was
assessed by determining PAI-1 levels, which were measured using
Technoclone GmbH assay kits (Vienna, Austria). The intra-assay
CVs were 4.9 and 5.8%.
Proinflammatory factors (interleukin-6, IL-6; eBioscience,
Vienna, Austria) and C-reactive protein (CRP) (Biomerica,
Irvine, CA, USA) were assessed using standard test kits
(CV, 7.03–8.99%, and CV, 2.3-4.1%) Serum glucose, insulin,
and C-peptide levels were measured to assess carbohydrate
metabolism and to diagnose IR. The homeostasis model
assessment of IR (HOMA-IR) index was calculated on days 1 and
12 after MI onset. A HOMA-IR value > 2.77 was established as
the cut-off value indicating IR.
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Statistical Analysis
Statistical analysis was performed using Statistica 6.1. software
(InstallShield Software Corp., Chicago, IL, USA). Results are
presented as median (Me) and 25 and 75% quartiles Me (Q1;Q3).
Statistical analyses were performed using the nonparametric
Mann–Whitney test for unpaired samples and the Wilcoxon
test for paired samples. Spearman’s correlation coefficient was
calculated to analyze correlations between variables.
RESULTS
Atorvastatin was generally well-tolerated, except in one patient.
In that case, the drug administration was discontinued because
of the development of dyspepsia. The patient experienced nausea
within a week of beginning treatment with atorvastatin.
The groups were well-matched for sex, age, and presence of
cardiovascular risk factors, such as hypertension, smoking,
and overweight. Over 41% of patients in both groups
had a family history of coronary artery disease (Table 1).
Chronic pyelonephritis and peptic ulcer disease prevailed
among comorbidities. The activity of CPK-MB did not differ
significantly in both groups [Group 1, 129.6 (111.4;135.6) U/L,
Group 2, 146.3 (121.5;156.2) U/L, p = 0.942]. No clinical signs
of congestive heart failure were observed in roughly 80% of
patients in both groups, which was estimated using the Killip
classification at the time of admission and during the follow-
up period (Killip and Kimball, 1967). Over 40% of patients
experienced arrhythmias and were diagnosed according to the
generally accepted criteria (Kryzhanovsky, 2001). The parameters
of the structural and functional states of the left ventricle did not
differ significantly between the groups. The mean left ventricular
ejection fraction was 53.5 (52.2;54.4)% in Group 1 and 45.2
(43.5;46.2)% in Group 2 (p = 0.385). Mean left ventricular
end-diastolic volume was 153.2 (151.6;154.4)mL in Group 1 and
154.4 (151.3;16.9)mL in Group 2 (p = 0.768), whereas mean left
ventricular end-systolic volume was 67.2 (65.4;69.5) in Group 1
and 74.2 (73.2;77.8)± 7.8 mL in Group 2 (p= 0.14). Both groups
were comparable for coronary atherosclerotic lesions: 14 (66.7%)
patients in Group 1 and 10 (45.5%) patients in Group 2 had
multivessel (more than three-vessel disease) coronary disease
(p = 0.688) according to the results of coronary angiography
performed at the time of admission. Percutaneous coronary
intervention of the infarct-dependent artery was performed as
reperfusion therapy in all patients.
The lipid profile showed significant changes in both groups
at the time of hospital admission. These changes were commonly
regarded as indicators of active atherogenetic process and risk for
cardiovascular disease: elevated levels of total cholesterol, LDL-
C, apo-B, apo-B/apo A1 ratio, TAG, and decreased levels of HDL
cholesterol and Apo-A (Table 2).
Group 1 patients who received atorvastatin showed decreased
total cholesterol levels and increased apo-A levels after 12 days
of treatment. Group 2 patients, who did not receive statins,
showed lower total cholesterol levels, but significantly high levels
of LDL-C, apo-B, apo-B/apo A1 ratio, VLDL-C, and TAG.
TABLE 1 | Clinical and demographic data of the patient cohort, n (%).
Variable MI patients P
Group 1, n = 66 Group 2, n = 60
Men, n (%) 58 (87.8) 55 (91.6) 0.862
Age, years 60.4 (56.6;62,3) 56.5 (52,3;61,2) 0.118
CAD RISK FACTORS
Arterial hypertension, n (%) 52 (78.7) 55 (91.6) 0.861
Current smoking, n (%) 45 (68.2) 50 (83.3) 0.854
Family history of ischemic
heart disease, n (%)
30 (45.5) 29 (48.3) 0.911
BMI, kg/m2 26.8 (24.8;27.5) 27 (25.5;28.6) 0.445
PRIOR MEDICAL HISTORY
Angina pectoris signs prior
to MI onset
33 (50.0) 29 (48.3) 0.914
Prior MI 12 (18.2) 9 (15) 0.858
A positive history of acute
cerebrovascular
accidents/transient
ischemic attacks
3 (4.6) 0 0.641
COMORBIDITIES
Chronic bronchitis n (%) 6 (9.1) 5 (8.3) 0.786
Bronchial asthma, n (%) 3 (4.6) 5 (8.3) 0.641
Ulcerous disease in
remission n (%)
3 (4.6) 5 (8.3) 0.786
Chronic pyelonephritis n (%) 9 (13.6) 12 (20) 0.858
DEPTH OF LESION
MI
- Q-wave 48 (72.7) 42 (70) 0.927
- non Q-wave 18 (27.3) 18 (30) 0.894
MI localization
- Posterior; 36 (54.5) 28 (46.6) 0.833
- Posterior and RV; 14 (21.2) 13 (21.6) 0.99
- Anterior 16 (24.2) 19 (31.7) 0.781
- Circular 0 5 (8.3) 0.641
POST-MI COMPLICATIONS (IN-HOSPITAL PERIOD)
ACF (Killip)
I 54 (81.8) 46 (76.6) 0.99
II 8 (12.1) 7 (11.6) 0.99
III 4 (6.1) 7 (11.6) 0.786
IV 0 0 0.99
Complications followed MI (in the in-hospital period)
- Arrhythmias 27 (40.9) 27 (45) 0.911
- Early post-infarction
angina pectoris
12 (18.2) 15 (25) 0.762
IN-HOSPITAL TREATMENT
- β-AB 65 (98.5) 60 (100) 0.936
- ACEs 57 (84.4) 49 (81.6) 0.932
- CCB 60 (90.9) 60 (100) 0.871
- Diuretics 24 (36.4) 28 (46.6) 0.818
- Nitrates 12 (18.2) 15 (25) 0.762
- Aspirin 63 (95.5) 60 (100) 0.936
- Heparin 63 (95.5) 60 (100) 0.936
- Clopidogrel 63 (95.5) 60 (100) 0.935
MI, myocardial infarction; CAD, coronary artery disease; ACE, angiotensin-converting
enzyme; CCB, calcium channel blockers; β-AB, beta blockers; ACEs, angiotensin-
converting-enzyme inhibitor.
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TABLE 2 | Parameters of lipid transport function in blood and adipokine profile on days 1 and 12 after onset of MI.
Variable Controls (n = 40) Group 1 Group 2
Day 1 Day 12 Day 1 Day 12
TC, mmol/L 4.5 (3.8;4.6) 5.80 (5.3;7.4)a 5.23 (4.86;5.42)c 5.59 (5.2;6.9)a 5.35 (4.96;6.52)
LDL, mmol/L 2.56 (2.1;2.76) 2.52 (2.2;3.01)a 2.36 (1.7;3.01) 2.54 (2.45;2.89)a 2.84 (2.75;3,53)c
HDL, mmol/L 1.26 (1.1;1.3) 0.88 (0.8;1.1)a 0.95 (0.77;1.13) 1.02 (0.98;1,12)a 1.11 (0,99;1,23)
VLDL, mmol/L 0.56 (0.4;0.9) 1.10 (0.9;1.4)a 1.03 (0.71;1.46)a 0.98 (0.95;1.12)a 1.26 (1.19;1.38)c
Apo-A, g/l 1.54 (1.3;1.65) 1.10 (0.9;1.3)a 1.23 (1.0;1.6)a,b 1.25 (1.12;1.35)a 1.50 (1.39;1.65)c
Apo-B, g/l 1.19 (1.0;1.5) 1.75 (1.2;1.9)a 1.43 (1.32;1.50) 1.40 (1.32;1.46)a 1.67 (1.58;1.76)c
TAG, mmol/L 1.20 (1.1;1.5) 2.17 (1.5;3.4)a 1.98 (1.85;2.01) 1.99 (1.87;2.23)a 2.34 (2.25;2.45)c
apo-B/apo-A1 ration 0.81 (0.7;1.0) 1.48 (0.9;1.8)a 0.92 (0.87;1.11) 1.24 (1.19;1.31)a 1.33 (1.28;1.40)a,c
FFA, mmol/L 0.35 (0.2;0.4) 1.92 (1.0;2.0)a 0.52 (0.49;0.59)a,c 1.88 (1.85;1.97)a 0.87 (0.78;0.98)a,b,c
Leptin, ng/ml 6.2 (5.6;7.3) 26.32 (24.9;27.9)a 15.71 (14.9;16.87)a,c 23.81 (21.89;24.76)a 19.33 (18.12;20.76)a,b,c
Adiponectin, ng/ml 12.1 (9.4;13.5) 13.12 (12.43;14.67) 15.06 (13.76;16.12)a,c 9.61 (9.01;10.98) 10.18 (9.89;10.74)
TC, total cholesterol; TAG, triacylglycerol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; VLDL, very-low-density lipoprotein cholesterol; apo-B,
apolipoprotein B; apo-A1, apolipoprotein A.
aSignificant difference from control, (p < 0.05);
bStatistically significant differences in parameters between Group 1 and 2 on day 12, (p < 0.05);
cSignificant differences in parameters within one group on days 1 and 12, (p < 0.05).
Among the parameters of lipid metabolism, the most
pronounced changes were observed in FFA levels (Table 2).
On day 1 after MI, FFA levels in both groups showed a 9-
fold increase compared with the control group. During the
hospitalization period, FFA levels decreased in both groups,
particularly in Group 1. In this group, FFA levels decreased
by 83.3% compared with baseline values, whereas in Group 2,
FFA levels were decreased by 53.5%. However, FFA levels were
higher in both groups compared with those in the Control group
(Table 2).
On day 1 of MI, patients had a 2.9- to 3.3-fold increase
in leptin levels compared with the control group. Atorvastatin
therapy (Group 1) resulted in a decrease in leptin levels by 40.3%
and was significantly lower compared with the patients in Group
2 (Table 2). The assessment of the adiponectin/leptin ratio in
patients with MI reported its significant decrease in all patients
at the time of admission [mean values of 0.5 (0.48;0.52) to 0.38
(0.378;0.391) in Groups 1 and 2, respectively], compared with
the ratio in the control group [mean values of 1.44 (1.43;1.448)].
The initiation of atorvastatin therapy increased the ratio values
owing to the increased levels of adiponectin. However, this ratio
remained at baseline values in patients who did not receive
atorvastatin.
The results of the carbohydrate metabolism assessment are
presented in Table 3. MI patients in both groups on day 1 showed
a 1.5- to 1.6-fold increase in glucose levels, compared with
the control group. Administration of therapies in both groups
resulted in statistically significant reductions in glucose levels.
Moreover, patients receiving atorvastatin presented with normal
glucose levels, as those observed in healthy subjects (3.5–5.8
mmol/L). Further, beneficial effects of statins were demonstrated
by C-peptide levels decreased by 37.6% compared with baseline
values. C-peptide levels after treatment were significantly lower
compared with those in patients who did not receive atorvastatin.
Despite the fact that insulin levels did not vary significantly
during the follow-up period, the integral index of IR, HOMA-
IR, had undergone significant changes. On day 1, HOMA-
IR index increased 1.3-fold in Group 1 and 1.5-fold in
Group 2 compared with the control group. The 12 day
atorvastatin treatment showed a significant decrease in HOMA-
IR by17.4% (2.1 [2.2;3.1]); its value decreased to normal.
Group 2 patients who did not receive statins demonstrated
elevated HOMA-IR, indicating the presence of moderate IR.
PAI-1 levels in MI patients increased from 3.5- to 4.0-fold
in comparison with the control group (Table 4). After 12-day
atorvastatin treatment, PAI-1 levels significantly decreased by
35.3% compared with baseline values. PAI-1 levels remained 3.6
times higher in Group 2 patients, compared with the control
group.
On day 1 of MI, CRP increased 23- to 25-fold, and IL-6
demonstrated a 6- to 7-fold increase compared with the control
group (Table 4). Atorvastatin therapy reduced CRP levels by
23.1% and IL-6 levels by 49.2% in Group 1 compared with
baseline values. However, patients receiving standard treatment
reported a decrease in IL-6 levels by 31.7%.
DISCUSSION
Large prospective clinical studies have shown the positive effects
of statin therapy on the long-term prognosis of patients with MI
(Gotto et al., 2000; Pedersen et al., 2004); however, the effects
of statins in an in-hospital setting in patients with MI are not
clearly understood. A well-studied mechanism of statin activity
is inhibition of HMG-CoA reductase, which enables the effective
reduction of blood cholesterol levels (Bakker-Arkema et al., 1996;
Rodríguez-Calvo et al., 2009). In our study, atorvastatin therapy,
administered early on during the hospitalization of patients with
MI, resulted in decreased total cholesterol levels.
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TABLE 3 | Markers of insulin resistance in patients with myocardial infarction on days 1 and 12 after MI onset.
Variable Controls (n = 40) Group 1 Group 2
Day 1 Day 12 Day 1 Day 12
Insulin, mU/mL 11.6 (10.9;12,5) 12.55 (11.28;13.1) 10.81 (10,12;11.56) 12.73 (11.89;13.6) 11.79 (10.96;13,0)
C-peptide, ng/mL 1.4 (1.2;2.1) 1.8 (1.6;1.9)a 1.1 (0.8;1.9)b,c 1.61 (1.39;1,71)a 1.22 (1.12;1.34)c
Glucose, mmol/L 4.5 (4.1;5.2) 6.4 (5.9;6.8)a 5.48 (4.78;6.21)c 6.18 (5.89;7.94)a 5.6 (4,89;6.1)
HOMA-IR 2.6 (2.4;2.6) 3.3 (2.9;3.6)a 2.1 (2.2;3.1)b,c 3.71 (2.98;4.45)a 3.41 (2.67;4.56)a
MI, myocardial infarction; HOMA-IR, homeostasis model assessment of insulin resistance.
aStatistically significant differences with the control group, (p < 0.05);
bStatistically significant differences in parameters between Group 1 and 2 on day 12, (p < 0.05);
cSignificant differences in parameters within one group on days 1 and 12, (p < 0.05).
TABLE 4 | Levels of plasminogen activator inhibitor, interleukin 6, and C-reactive protein in patients with myocardial infarction on day 1 and 12 of
hospitalization.
Variable Controls (n = 40) Group 1 Group 2
Day 1 Day 12 Day 1 Day 12
Plasminogen activator inhibitor, ng/ml 35.3 (32.1;43.2) 125.9 (112.5;156.6)a 81.4 (75.6;92.5)a,b,c 144.61 (123.5;165.4)a 133.38 (123.6;154.2)a
C-reactive protein, mg/L 1.05 (0.8;1.5) 27.44 (26.3;30.8)a 20.88 (18.96;22.98)a,c 25.66 (24,31;26,87)a 24.27 (22.34;25.12)a
IL-6, pg/ml 3.90 (3.87;4.23) 22.66 (21.93;23.89)a 11.61 (10.87;12.56)a,c 20.35 (19.65;21.67)a 14.38 (13.56;15.45)a,c,d
aStatistically significant differences with the control group, (p < 0.05);
bStatistically significant differences in parameters between Group 1 and 2 on day 1, (p < 0.05);
cStatistically significant differences in parameters between Group 1 and 2 on day 12, (p < 0.05);
dSignificant differences in parameters within one group on days 1 and 12, (p < 0.05).
According to the results of this study, the most pronounced
change among the lipid metabolism parameters in MI patients
receiving atorvastatin was the reduction of FFA levels, which
could be explained by decreased FFA synthesis in the liver. Recent
experimental studies reported that rats that were fed a fructose-
rich diet showed elevated TAG levels and developed metabolic
syndrome. Those treated with atorvastatin resulted in a decrease
of FFA and TAG levels (Rodríguez-Calvo et al., 2009).The authors
suggested that atorvastatin treatment blocked the activation of
the carbohydrate response element binding protein (ChREBP),
responsible for the synthesis of FFA from carbohydrates.
Moreover, it is possible that atorvastatin treatment improves
the use of FFA in the myocardial tissue of MI patients by
peroxisome proliferator-activated receptors, which are involved
in the cardiomyocyte energy metabolism (Rodríguez-Calvo et al.,
2009).
Elevated FFA levels are now regarded as a marker of IR
(Dresner et al., 1999). Thus, their reduction after atorvastatin
therapy suggests a decrease in IR in patients with MI treated
early on during hospitalization. This positive effect of the drug
was confirmed by other changes in the parameters responsible
for tissue sensitivity to insulin. We observed a significant
decrease in the levels of C-peptide, serum glucose, and HOMA-
IR after 12 days of atorvastatin treatment. Further, the values
of the latter parameter were comparable to those in the control
group. These results are consistent with those of other authors,
confirming the beneficial effects of statins on peripheral tissue
sensitivity to insulin and carbohydrate metabolism (Dresner
et al., 1999).
In recent years, the roles of adipokines, leptin, and adiponectin
have been actively discussed in the development of MI and
its complications. Leptin and adiponectin are responsible for
maintaining energy and metabolic homeostasis in physiological
conditions. Normally, leptin protects the peripheral tissues
from excessive accumulation of FFA, primarily by regulating
feeding behavior in the hypothalamus. It is hypothesized that
hyperleptinemia is concurrent with the development of IR,
and thus, causes pathological changes in the cardiovascular
system (Martin et al., 2008). Wallander et al. (2008) suggested
that high leptin levels in the blood serum should be regarded
as a predictor for recurrent cardiovascular events as well as
for the development of carbohydrate intolerance in patients
with MI. Unlike leptin, adiponectin plays a protective role,
potentiating insulin effects on endothelial function, vessel wall
tone, and platelet aggregation. The possible anti-atherogenic
effect of adiponectin is currently under discussion, and its low
level is seen as an indicator of IR, a high risk of developing
metabolic syndrome and cardiovascular disease (Li et al., 2009).
In this study, hyperleptinemia was found in all MI patients
at the time of admission, and the subsequent 12 day therapy,
especially in patients treated with atorvastatin, contributed to a
marked reduction in plasma leptin levels. Furthermore, statin
therapy showed a significant increase in adiponectin levels
and the adiponectin/leptin ratio that can be regarded as a
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favorable effect of atorvastatin, which contributes by reducing
the imbalance of adipokines and normalizing lipid metabolism
in general.
Perhaps this is due to the effect of atorvastatin on balance
adipoktine /fibroblast growth factor. As known, the functioning
of adiponectin closely related fibroblast growth factor 21
(FGF21). Both hormones have multiple protective effects against
cardiovascular diseases and metabolic dysfunction (Hui et al.,
2016). Despite the fact that FGF21 and adiponectin have
different structures and synthetic sources, these two hormones
have striking functional similarity. In adipocytes transcription
and secretion is induced adiponectin FGF21, which is partly
dependent on the activity of PPARgamma. FGF21/adiponectin-
axis protects from a variety of cardio-metabolic disorders
through multiple organ mediating communication and is a
promising target for therapeutic intervention in chronic diseases
(Hui et al., 2016).
Current understanding of the pathogenesis of MI is based
not only on the dyslipidemic theory and adipokine imbalance,
there has been considerable emphasis on the activation of systems
triggering inflammatory mechanisms and inducing disorders
of the fibrinolytic system. Our results showed that levels of
inflammatory markers, CRP and IL-6, were significantly higher
in both groups of patients in the acute phase of MI, and in the
early hospitalization period compared with the control group.
It should be noted that atorvastatin treatment was accompanied
by anti-inflammatory effects in the early in-hospital period,
resulting in reduced CRP and IL-6 levels, which is also consistent
with the results Gupta et al. (2008) who showed the efficacy of
statin treatment within 4–6 weeks.
A significant reduction of PAI-1 levels in the hospitalization
period was also determined after atorvastatin treatment. PAI-1 is
considered to be a risk factor for atherothrombosis and MI, as
well as a marker of IR, according to the results of current studies
(Gotto et al., 2000). Alessi and Juhan-Vague (2006) suggested that
obese patients with hyperinsulinemia and a genotype associated
with increased transcription of PAI-1 were at high risk of
developing MI. According to our findings, early effects of
atorvastatin, manifested after 12 days of therapy, notably enhance
the understanding of the pharmacological effects of statins and
confirm their beneficial effects on the lipid metabolism after
MI, thereby possibly preventing the development of further
complications.
CONCLUSION
The effects of treatment with atorvastatin 20 mg/day were shown
during the early recovery period among patients with MI. The
findings of the present study further confirm its pleiotropic
effects. In addition to its lipid-lowering and anti-inflammatory
effects, statin therapy reduced the severity of IR, based on
reduced levels of FFA, IL-6, PAI-1, and improved adipokine
status. All these parameters increase the efficacy of treatment
in patients with MI and contribute to the improvement of their
prognosis after hospital discharge.
LIMITATIONS
Limitations of this study the outcomes are just biological index
without clinical adverse events, which decrease its direction in
clinical practice. And the short period of the observation also
weaken the application and significance of this conclusion.
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